KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBT Margin (2018 - 2025)

Castle Biosciences (CSTL) has disclosed EBT Margin for 8 consecutive years, with 3.12% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1225.0% to 3.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.57% through Dec 2025, down 1507.0% year-over-year, with the annual reading at 8.57% for FY2025, 1507.0% down from the prior year.
  • EBT Margin hit 3.12% in Q4 2025 for Castle Biosciences, down from 0.46% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 9.65% in Q3 2024 to a low of 91.2% in Q1 2022.
  • Historically, EBT Margin has averaged 25.45% across 5 years, with a median of 14.97% in 2023.
  • Biggest five-year swings in EBT Margin: tumbled -7244bps in 2022 and later soared 6603bps in 2024.
  • Year by year, EBT Margin stood at 60.53% in 2021, then rose by 11bps to 53.63% in 2022, then skyrocketed by 93bps to 3.84% in 2023, then skyrocketed by 338bps to 9.14% in 2024, then tumbled by -134bps to 3.12% in 2025.
  • Business Quant data shows EBT Margin for CSTL at 3.12% in Q4 2025, 0.46% in Q3 2025, and 0.17% in Q2 2025.